<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> in the gut lumen activates gut <z:chebi fb="32" ids="24621">endocrine</z:chebi> cells to release <z:chebi fb="0" ids="28790">5-HT</z:chebi>, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1/2 (GLP-1/2), and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (GIP), which act to change gastrointestinal function and regulate postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>There is evidence that both release and action of incretin hormones is reduced in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) </plain></SENT>
<SENT sid="2" pm="."><plain>We measured cellular activation of enteroendocrine and enterochromaffin cells, enteric neurons, and vagal afferent neurons in response to intestinal <z:chebi fb="105" ids="17234">glucose</z:chebi> in a model of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, the UCD-T2DM rat </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">Prediabetic</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), recent-diabetic (RD, 2 wk postonset), and 3-mo diabetic (3MD) fasted UCD-T2DM rats were given an orogastric gavage of vehicle (water, 0.5 ml /100 g body wt) or <z:chebi fb="105" ids="17234">glucose</z:chebi> (330 Î¼mol/100 g body wt); after 6 min tissue was removed and cellular activation was determined by immunohistochemistry for phosphorylated calcium calmodulin-dependent kinase II (pCaMKII) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> rats, pCaMKII immunoreactivity was increased in duodenal <z:chebi fb="0" ids="28790">5-HT</z:chebi> (P &lt; 0.001), K (P &lt; 0.01) and L (P &lt; 0.01) cells in response to <z:chebi fb="105" ids="17234">glucose</z:chebi>; <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced activation of <z:hpo ids='HP_0000001'>all</z:hpo> three cell types was significantly reduced in RD and 3MD compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> rats </plain></SENT>
<SENT sid="5" pm="."><plain>Immunoreactivity for GLP-1, but not GIP, was significantly reduced in RD and 3MD compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> rats (P &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of <z:chebi fb="105" ids="17234">glucose</z:chebi> significantly increased pCaMKII in enteric and vagal afferent neurons in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> rats; <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced pCaMKII immunoreactivity was attenuated in enteric and vagal afferent neurons (P &lt; 0.01, P &lt; 0.001, respectively) in RD and 3MD </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that <z:chebi fb="105" ids="17234">glucose</z:chebi> sensing in enteroendocrine and enterochromaffin cells and activation of neural pathways is markedly impaired in UCD-T2DM rats </plain></SENT>
</text></document>